Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
- PMID: 35679156
- PMCID: PMC9387686
- DOI: 10.1210/clinem/dgac340
Correction to: Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
Erratum for
-
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?J Clin Endocrinol Metab. 2022 Jun 16;107(7):e3003-e3007. doi: 10.1210/clinem/dgac154. J Clin Endocrinol Metab. 2022. PMID: 35290464 Free PMC article. Clinical Trial.
